Analysts Set Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Price Target at $77.20

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has earned a consensus rating of “Buy” from the seventeen research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, fourteen have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $77.20.

XENE has been the topic of several analyst reports. Needham & Company LLC dropped their price target on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Wells Fargo & Company restated an “overweight” rating and issued a $69.00 price objective on shares of Xenon Pharmaceuticals in a research note on Sunday, May 10th. Royal Bank Of Canada raised their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. JPMorgan Chase & Co. lifted their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research report on Wednesday, May 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Monday, July 6th.

Insider Activity at Xenon Pharmaceuticals

In other news, Director Gary Patou sold 1,322 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the sale, the director directly owned 24,896 shares in the company, valued at $1,322,973.44. This trade represents a 5.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the transaction, the director owned 1,455 shares in the company, valued at approximately $77,318.70. This trade represents a 44.99% decrease in their position. The SEC filing for this sale provides additional information. 2.91% of the stock is owned by insiders.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Danske Bank A S bought a new stake in Xenon Pharmaceuticals during the 3rd quarter valued at approximately $32,000. Blue Trust Inc. boosted its stake in Xenon Pharmaceuticals by 2,560.7% in the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 717 shares during the period. Kestra Advisory Services LLC purchased a new stake in Xenon Pharmaceuticals during the 4th quarter valued at approximately $33,000. Osaic Holdings Inc. grew its holdings in Xenon Pharmaceuticals by 541.4% during the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 1,034 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Xenon Pharmaceuticals during the 4th quarter valued at approximately $43,000. 95.45% of the stock is owned by institutional investors.

Xenon Pharmaceuticals Stock Down 0.8%

NASDAQ XENE opened at $66.18 on Monday. The company has a 50-day moving average price of $57.89 and a 200-day moving average price of $52.38. Xenon Pharmaceuticals has a 52 week low of $30.00 and a 52 week high of $72.66. The firm has a market capitalization of $6.40 billion, a P/E ratio of -14.08 and a beta of 0.61.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.17). During the same quarter in the previous year, the company posted ($0.83) earnings per share. As a group, equities research analysts anticipate that Xenon Pharmaceuticals will post -4.92 EPS for the current year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.